204 related articles for article (PubMed ID: 33325646)
1. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Zhao B; Shen J; Zhao J; Pan H
J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.
Qiu M; Ding LL; Zhang M; Zhou HR
J Diabetes Complications; 2021 Feb; 35(2):107803. PubMed ID: 33293207
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
García M; Arteche-Martinez U; Lertxundi U; Aguirre C
J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
Menne J; Dumann E; Haller H; Schmidt BMW
PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
8. Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
Mannucci E; Monami M
Drug Saf; 2017 Feb; 40(2):115-119. PubMed ID: 27826881
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
[TBL] [Abstract][Full Text] [Related]
10. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
12. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Khouri C; Cracowski JL; Roustit M
Diabetes Obes Metab; 2018 Jun; 20(6):1531-1534. PubMed ID: 29430814
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database.
Zhao H; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1110575. PubMed ID: 36865915
[No Abstract] [Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
Azharuddin M; Adil M; Ghosh P; Sharma M
Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
[TBL] [Abstract][Full Text] [Related]
16. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
17. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
18. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
19. Initiation of dapagliflozin and treatment-emergent fractures.
Toulis KA; Bilezikian JP; Thomas GN; Hanif W; Kotsa K; Thayakaran R; Keerthy D; Tahrani AA; Nirantharakumar K
Diabetes Obes Metab; 2018 Apr; 20(4):1070-1074. PubMed ID: 29193543
[TBL] [Abstract][Full Text] [Related]
20. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
